Payment overview · 2025
General Payments
$747.50
14 reported records · 4 companies
Healthcare provider profile · identity verified
Paul E Emmans, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · YAKIMA, WA · NPI 1033130646
Verified facts
What the public records show
CMS Open Payments records show Paul E Emmans, D.O. received $747.50 in general payments during 2025 across 14 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 46.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza, Lokelma.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BYETTA as an associated drug or biological on 60 records involving 49 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Byetta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Symbicort by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ingrezza by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $347.76 | 46.5% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $185.17 | 24.8% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $138.16 | 18.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $76.41 | 10.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $747.50 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $347.76 | 8 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $138.16 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $121.20 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $76.41 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $63.97 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BYETTA open payments reported associated product |
CMS Open Payments — General Payments 60 supporting records · 49 recipient NPIs · example record 1206154618 |
Byetta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
139 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1771 | 257 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1113 | 163 |
| Eliquis | Apixaban | 884 | 94 |
| Gabapentin | Gabapentin | 861 | 135 |
| Furosemide | Furosemide | 834 | 127 |
| Potassium Chloride | Potassium Chloride | 775 | 129 |
| Amlodipine Besylate | Amlodipine Besylate | 688 | 118 |
| Metoprolol Succinate | Metoprolol Succinate | 621 | 111 |
| Lisinopril | Lisinopril | 608 | 98 |
| Sertraline Hcl | Sertraline Hcl | 524 | 97 |
| Losartan Potassium | Losartan Potassium | 509 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 496 | 91 |
| Tamsulosin Hcl | Tamsulosin Hcl | 484 | 79 |
| Metformin Hcl | Metformin Hcl | 450 | 81 |
| Quetiapine Fumarate | Quetiapine Fumarate | 405 | 66 |
| Trazodone Hcl | Trazodone Hcl | 376 | 79 |
| Famotidine | Famotidine | 363 | 60 |
| Omeprazole | Omeprazole | 352 | 68 |
| Duloxetine Hcl | Duloxetine Hcl | 349 | 51 |
| Warfarin Sodium | Warfarin Sodium | 331 | 31 |
| Carvedilol | Carvedilol | 328 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 312 | 61 |
| Donepezil Hcl | Donepezil Hcl | 310 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 310 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 307 | 46 |
| Divalproex Sodium | Divalproex Sodium | 297 | 57 |
| Lactulose | Lactulose | 294 | 58 |
| Levetiracetam | Levetiracetam | 294 | 40 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 255 | 47 |
| Risperidone | Risperidone | 251 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 241 | 41 |
| Baclofen | Baclofen | 240 | 41 |
| Mirtazapine | Mirtazapine | 211 | 54 |
| Memantine Hcl | Memantine Hcl | 201 | 29 |
| Xarelto | Rivaroxaban | 192 | 17 |
| Spironolactone | Spironolactone | 187 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 165 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 158 | 49 |
| Nystatin | Nystatin | 154 | 71 |
| Fluoxetine Hcl | Fluoxetine Hcl | 153 | 15 |
| Tradjenta | Linagliptin | 152 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 150 | 30 |
| Nystop | Nystatin | 149 | 62 |
| Tizanidine Hcl | Tizanidine Hcl | 149 | 24 |
| Jardiance | Empagliflozin | 145 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 14 |
| Farxiga | Dapagliflozin Propanediol | 139 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 139 | 82 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 129 | 53 |
| Simvastatin | Simvastatin | 126 | 21 |
| Allopurinol | Allopurinol | 124 | 28 |
| Metformin Hcl Er | Metformin Hcl | 120 | 28 |
| Tramadol Hcl | Tramadol Hcl | 118 | 42 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 117 | 16 |
| Finasteride | Finasteride | 116 | 19 |
| Insulin Lispro | Insulin Lispro | 116 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 114 | 33 |
| Latanoprost | Latanoprost | 111 | 24 |
| Torsemide | Torsemide | 109 | 19 |
| Fenofibrate | Fenofibrate | 101 | 14 |
| Montelukast Sodium | Montelukast Sodium | 99 | 20 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 97 | 97 |
| Carbamazepine | Carbamazepine | 96 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 96 | 14 |
| Myrbetriq | Mirabegron | 93 | 12 |
| Prazosin Hcl | Prazosin Hcl | 91 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 91 | 30 |
| Clonazepam | Clonazepam | 90 | 21 |
| Humalog | Insulin Lispro | 90 | 28 |
| Buspirone Hcl | Buspirone Hcl | 89 | 19 |
| Aptiom | Eslicarbazepine Acetate | 88 | suppressed |
| Digoxin | Digoxin | 87 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 56 |
| Lamotrigine | Lamotrigine | 84 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 14 |
| Pregabalin | Pregabalin | 83 | 27 |
| Benztropine Mesylate | Benztropine Mesylate | 81 | 14 |
| Olanzapine | Olanzapine | 80 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 77 | 14 |
| Prednisone | Prednisone | 77 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 77 | 12 |
| Januvia | Sitagliptin Phosphate | 76 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 75 | 73 |
| Cephalexin | Cephalexin | 72 | 47 |
| Diclofenac Sodium | Diclofenac Sodium | 72 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 11 |
| Albuterol Sulfate | Albuterol Sulfate | 66 | 26 |
| Lorazepam | Lorazepam | 65 | 30 |
| Bupropion Xl | Bupropion Hcl | 64 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 64 | 32 |
| Clonidine Hcl | Clonidine Hcl | 61 | suppressed |
| Azithromycin | Azithromycin | 60 | 16 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 60 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 59 | 12 |
| Dilt-Xr | Diltiazem Hcl | 59 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 55 | 23 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 55 | 32 |
| Aripiprazole | Aripiprazole | 52 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 52 | suppressed |
| Ondansetron Odt | Ondansetron | 52 | 37 |
| Oxybutynin Chloride | Oxybutynin Chloride | 51 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 50 | suppressed |
| Scopolamine | Scopolamine | 50 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Lovastatin | Lovastatin | 49 | 11 |
| Ozempic | Semaglutide | 49 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 19 |
| Atenolol | Atenolol | 46 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 45 | 21 |
| Symbicort | Budesonide/Formoterol Fumarate | 45 | 11 |
| Bydureon Bcise | Exenatide Microspheres | 44 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 44 | suppressed |
| Austedo Xr | Deutetrabenazine | 43 | suppressed |
| Glipizide | Glipizide | 43 | suppressed |
| Meloxicam | Meloxicam | 42 | suppressed |
| Levemir | Insulin Detemir | 41 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 40 | suppressed |
| Methimazole | Methimazole | 40 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 40 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 40 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 39 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 39 | suppressed |
| Buprenorphine | Buprenorphine | 38 | 12 |
| Metolazone | Metolazone | 38 | suppressed |
| Paliperidone Er | Paliperidone | 38 | suppressed |
| Creon | Lipase/Protease/Amylase | 37 | suppressed |
| Levocarnitine | Levocarnitine | 37 | suppressed |
| Haloperidol | Haloperidol | 36 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 36 | 18 |
| Primidone | Primidone | 36 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 35 | suppressed |
| Methotrexate | Methotrexate Sodium | 35 | suppressed |
| Trulicity | Dulaglutide | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Insulin Aspart | Insulin Aspart | 34 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | 13 |
| Fentanyl | Fentanyl | 32 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 32 | suppressed |
| Methocarbamol | Methocarbamol | 32 | 11 |
| Novolog Flexpen | Insulin Aspart | 32 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 31 | 15 |
| Diltiazem 24hr Er | Diltiazem Hcl | 31 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 31 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 31 | suppressed |
| Anastrozole | Anastrozole | 30 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 30 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 30 | 17 |
| Lidocaine | Lidocaine | 30 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 29 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Calcitriol | Calcitriol | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | 23 |
| Oxcarbazepine | Oxcarbazepine | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 12 |
| Rivastigmine | Rivastigmine | 27 | suppressed |
| Acetic Acid | Acetic Acid | 26 | suppressed |
| Novolog | Insulin Aspart | 26 | 13 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 26 | suppressed |
| Xifaxan | Rifaximin | 26 | suppressed |
| Amantadine | Amantadine Hcl | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 23 |
| Brimonidine Tartrate | Brimonidine Tartrate | 25 | suppressed |
| Budesonide | Budesonide | 25 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 25 | suppressed |
| Phenytoin | Phenytoin | 25 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | 13 |
| Movantik | Naloxegol Oxalate | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Calcium Acetate | Calcium Acetate | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Erythromycin | Erythromycin Base | 23 | suppressed |
| Prolia | Denosumab | 23 | 21 |
| Celecoxib | Celecoxib | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 21 | 15 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 11 |
| Dorzolamide Hcl | Dorzolamide Hcl | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Olanzapine Odt | Olanzapine | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Auryxia | Ferric Citrate | 19 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 19 |
| Gemtesa | Vibegron | 19 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 13 |
| Lokelma | Sodium Zirconium Cyclosilicate | 19 | suppressed |
| Mirabegron Er | Mirabegron | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Ingrezza | Valbenazine Tosylate | 17 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 17 | suppressed |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | 15 |
| Sucralfate | Sucralfate | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 16 | suppressed |
| Humulin R | Insulin Regular, Human | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Entacapone | Entacapone | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 14 |
| Lacosamide | Lacosamide | 15 | suppressed |
| Lamotrigine Er | Lamotrigine | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Trospium Chloride | Trospium Chloride | 15 | suppressed |
| Victoza 2-Pak | Liraglutide | 15 | suppressed |
| Byetta | Exenatide | 14 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 14 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Travoprost | Travoprost | 14 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Ethambutol Hcl | Ethambutol Hcl | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | suppressed |
| Leflunomide | Leflunomide | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Insulin Glargine Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Pulmicort Flexhaler | Budesonide | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $747.50 · 14 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, CAPLYTA, INGREZZA, Kerendia, LOKELMA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error